Finally, studies employing MEK1/2, H/K-Ras, and PI3K inhibitors (UO126, FTI277, and Ly294002, respectively) support the involvement of these signaling pathways in the chemotactic responsiveness of cancer cells to 1% plasma (Figure 2C). Here, KRAS is linked to cancer.